Table 1.
Characteristics of patients with RA and acute inflammation (control subjects).
| RA | Control | |
|---|---|---|
| N = 25 | N = 13 | |
| Age (years) | 58.2 (25–83) | 36.6 (20–61) |
| Gender (% female) | 89% | 31% |
| Disease duration | 11.7 (1–40) years | 19.8 (3–56) days |
| Treatment | Prednisolone 15 (63%) | – |
| Methotrexate 8 (33%) | – | |
| Biological drugs 8 (33%) | – | |
| ACPAs, positive patients (%) | 11/14 (79%) | – |
| RF, positive patients (%) | 18/23 (82%) | – |
| CRP (mg/dL) | 1.3 (0.1–5.8) | – |
| MMP3 (ng/mL) | 206.2 (53–596) | – |
ACPAs, anti-citrullinated protein antibodies; control, trauma patients; CRP, C-reactive protein; MMP3, matrix metalloproteinase 3; RA, patients with rheumatoid arthritis; RF, rheumatoid factor.